QSAR for non-nucleoside inhibitors of HIV-1 reverse transcriptase

被引:83
|
作者
Duchowicz, Pablo R.
Fernandez, Michael
Caballero, Julio
Castro, Eduardo A.
Fernandez, Francisco M.
机构
[1] Natl Univ La Plata, INIFTA, Div Quim Teor, Dept Quim,Fac Ciencias Exactas, RA-1900 La Plata, Argentina
[2] Univ Matanzas, Ctr Biotechnol Studies, Mol Modeling Grp, Matanzas 44740, Cuba
关键词
QSPR-QSAR; molecular descriptors; reverse transcriptase inhibitor; anti-HIV potency;
D O I
10.1016/j.bmc.2006.05.027
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
By means of QSAR algorithms we model the potency pIC(90) [mM] of 154 non-nucleoside reverse transcriptase inhibitors (NNRTI) of the wild-type HIV-1 virus, considered as the second generation analogues of Efavirenz. In addition, 56 inhibitors of the K-103N viral mutant form are also investigated. A pool of 1494 theoretical molecular descriptors provided mainly by the Dragon 5 software is explored by several methods of variable selection: forward stepwise regression, the replacement method, and the genetic algorithm approach. The optimal models found include up to seven parameters: R = 0.7991, Rt-20%-o = 0.7233 for the case of wild-type, and R = 0.9261, Rl-5%-o = 0.8802 for the K-103N mutation. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5876 / 5889
页数:14
相关论文
共 50 条
  • [1] HIV-1 non-nucleoside reverse transcriptase inhibitors
    Högberg, M
    Morrison, I
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (08) : 1189 - 1199
  • [2] Non-nucleoside inhibitors of HIV-1 reverse transcriptase
    Proudfoot, JR
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (08) : 971 - 982
  • [3] Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1
    Moreno, S
    Casado, JL
    Pérez-Elias, MI
    Dronda, F
    Antela, A
    Moreno, A
    Gutiérrez, C
    [J]. AIDS, 2003, 17 (09) : 1413 - 1414
  • [4] Mechanisms of resistance of HIV-1 reverse transcriptase to nucleoside and non-nucleoside inhibitors
    Boyer, PL
    Tantillo, C
    Ding, J
    Ferris, AL
    Clark, P
    Arnold, E
    Hughes, SH
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 10 : 6 - 6
  • [5] Conformational preferences of non-nucleoside HIV-1 reverse transcriptase inhibitors
    Parreira, RLT
    Abrahao, O
    Galembeck, SE
    [J]. TETRAHEDRON, 2001, 57 (16) : 3243 - 3253
  • [6] Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase
    Ruiz-Caro, J
    Basavapathruni, A
    Kim, JT
    Bailey, CM
    Wang, LG
    Anderson, KS
    Hamilton, AD
    Jorgensen, WL
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (03) : 668 - 671
  • [7] HIV-1 reverse transcriptase resistance to non-nucleoside inhibitors.
    Spence, RA
    Johnson, KA
    [J]. BIOPHYSICAL JOURNAL, 1996, 70 (02) : MP356 - MP356
  • [8] Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1
    Chan, JH
    Freeman, GA
    Tidwell, JH
    Romines, KR
    Schaller, LT
    Cowan, JR
    Gonzales, SS
    Lowell, GS
    Andrews, CW
    Reynolds, DJ
    St Clair, M
    Hazen, RJ
    Ferris, RG
    Creech, KL
    Roberts, GB
    Short, SA
    Weaver, K
    Koszalka, GW
    Boone, LR
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (05) : 1175 - 1182
  • [9] Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
    Famiglini, Valeria
    Silvestri, Romano
    [J]. MOLECULES, 2016, 21 (02):
  • [10] Halolactones are potent HIV-1 non-nucleoside reverse transcriptase inhibitors
    Han, Xin
    Wu, Haoming
    Dong, Chune
    Tien, Po
    Xie, Wei
    Wu, Shuwen
    Zhou, Hai-Bing
    [J]. RSC ADVANCES, 2015, 5 (13): : 10005 - 10013